Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 64

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 64
---
 as the “Predecessor” for periods prior to the closing of the acquisition.
Revium Rx, which includes consolidation of Lipovation subsequent to the acquisition, is the “Successor” for periods after
the closing of the Business Combination.

As a result of the application of the acquisition
method of accounting in the Successor period, the financial data for the Successor period are presented on a full step-up basis as a
result of the acquisition and are therefore not comparable to the financial statements of the Predecessor period that are not presented
on the same full step-up basis.

Overview

Successor for the three months period ended March 31, 2025, the Predecessor for the three months period ended March 31, 2024

The following tables present selected financial
data for the Successor for the three months period ended March 31, 2025 and the Predecessor for the three months period ended March 31,
2024.

|                                     |     |                            Successor |      |   |     |                          Predecessor |     |   |
|                                     |     | For the three months ended March 31, |      |   |     | For the three months ended March 31, |     |   |
|                                     |     |                                 2025 |      |   |     |                                 2024 |     |   |
| Operating expenses                  |     |                                      |      |   |     |                                      |     |   |
| Research and development expenses   |     |                                      |  218 |   |     |                                      | 570 |   |
| General and administrative expenses |     |                                      |  519 |   |     |                                      |  80 |   |
| Operating loss                      |     |                                      |  737 |   |     |                                      | 650 |   |
| Financial income, net               |     |                                      | (103 | ) |     |                                      |   * | ) |
| Net loss and comprehensive loss     |     |                                      |  634 |   |     |                                      | 650 |   |

| *) | less than 1 thousand |

Research and Development Expenses

Successor’s research and development
expenses totaled $218 thousand for the three months period ended March 31, 2025, representing a decrease of $352 thousand, or 61.7%,
compared to Predecessor’s $570 thousand for the same period. The research and development expenses comprise mainly from salaries
and